• Home
  • Our Mission
  • Our Science
  • Team
  • Careers
  • News & Publications
  • Contact
Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)

Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)

by Rachel Black | Jan 3, 2024 | Press Release

Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA) Read...
Genascence to Present at Biotech Showcase 2024

Genascence to Present at Biotech Showcase 2024

by Rachel Black | Dec 20, 2023 | Press Release

Genascence to Present at Biotech Showcase 2024 Read...
Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress

by Rachel Black | Oct 24, 2023 | Press Release

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company’s Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30 th Annual Congress Read...
Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

by Rachel Black | Oct 18, 2023 | Press Release

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer Read...

Recent Posts

  • Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)
  • Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
  • Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
  • Genascence Appoints Jeymi Tambiah as Chief Medical Officer
  • Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001 Gene Therapy for Knee Osteoarthritis (OA)

Recent Comments

    Archives

    • July 2025
    • May 2025
    • January 2025
    • October 2024
    • January 2024
    • December 2023
    • October 2023
    • February 2023
    • May 2022

    Categories

    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact | Privacy Policy

    ©2022. Genascence. All Rights Reserved. Site by GOODLAB